{"id":274871,"date":"2026-04-14T13:42:37","date_gmt":"2026-04-14T13:42:37","guid":{"rendered":"https:\/\/pharmeasy.in\/blog\/?p=274871"},"modified":"2026-04-14T13:42:38","modified_gmt":"2026-04-14T13:42:38","slug":"diagnostic-double-marker-vs-triple-marker-test-differences-timing-results-how-they-work-together","status":"publish","type":"post","link":"https:\/\/pharmeasy.in\/blog\/diagnostic-double-marker-vs-triple-marker-test-differences-timing-results-how-they-work-together\/","title":{"rendered":"Double Marker vs. Triple Marker Test: Differences, Timing, Results & How They Work Together\u00a0"},"content":{"rendered":"\n\n<\/head>

Table of Contents<\/p>\nToggle<\/span>

Introduction<\/a><\/li>
What Is a Double Marker Test?<\/a><\/li>
What Is a Triple Marker Test?<\/a><\/li>
Difference Between Double Marker and Triple Marker Test<\/a><\/li>
\u202fHow Do These Tests Work Together?<\/a><\/li>
When to Take These Tests?<\/a><\/li>
How Are These Tests Done?<\/a><\/li>
Who Should Take These Tests?<\/a><\/li>
Advantages of Double Marker and Triple Marker Tests<\/a><\/li>
Limitations of Double and Triple Marker Tests<\/a><\/li>
Safety and Risks of Double Marker and Triple Marker Tests<\/a><\/li>
Conclusion<\/a><\/li>
Frequently Asked Questions (FAQs)<\/a><\/li>
References<\/a><\/li><\/ul><\/nav><\/div>\n \n <\/span>\n $\"Join$ \n <\/a>\n
<\/span>Introduction<\/strong><\/span><\/h2>\n\n\n\nThe\u00a0pregnancy period involves several checkups, which\u00a0are\u00a0essential to\u00a0ensure that the\u00a0baby is growing well and staying healthy.\u00a0An\u00a0important part of these check-ups is\u00a0early pregnancy (prenatal)\u00a0screening, which helps doctors understand if there\u00a0are\u00a0any chances\u00a0of certain health conditions in the baby early on. These are simple screening tests, which are different from diagnostic procedures 1<\/a><\/sup>.\u00a0<\/p>\n\n\n\n
A type\u00a0of screening tests\u00a0employed for this purpose are the\u00a0marker tests. These are the blood tests which measure some natural components\u00a0(biomarkers)\u00a0in the mother\u2019s blood.\u00a0The levels of these markers can give an idea about the baby\u2019s risk of conditions, for e.g.,\u00a0some genetic conditions like\u00a0Down\u2019s\u00a0syndrome 2<\/a><\/sup>.<\/p>\n\n\n\n
These\u00a0marker tests\u00a0include\u00a0the\u00a0double marker test and the triple marker test. They are similar but done at\u00a0different stages\u00a0of pregnancy and check\u00a0different types\u00a0of markers 3<\/a>,4<\/a><\/sup>.<\/p>\n\n\n\n
In this article,\u00a0we\u2019ll\u00a0explain the\u00a0difference between double marker and triple marker tests, when they are performed, what their results say,\u00a0and how they can be employed together to assess\u00a0the baby\u2019s health.\u00a0<\/p>\n\n\n\n
<\/span>What Is a Double Marker Test?<\/strong><\/span><\/h2>\n\n\n\nThe double marker test<\/a><\/strong> is a\u00a0pregnancy\u00a0screening blood test, which helps assess the risk of certain genetic conditions in the baby during early pregnancy. It is usually performed as\u00a0a\u00a0part of\u00a0first-trimester\u00a0(first 3 months of pregnancy)\u00a0screening, which helps\u00a0determine\u00a0early indications\u00a0of whether further detailed testing may be needed 3<\/a><\/sup>.<\/p>\n\n\n\n
The test measures two specific markers present in the mother\u2019s blood:\u00a0<\/p>\n\n\n\n
\n
Free \u03b2-human chorionic gonadotrophin (free \u03b2-hCG):\u00a0<\/strong>A hormone produced during pregnancy\u00a0and is important for supporting pregnancy\u00a0<\/li>\n\n\n\n
Pregnancy-associated plasma protein A (PAPP-A):<\/strong>\u00a0A protein\u00a0produced by\u00a0the\u00a0placenta\u00a0(tissue that attaches baby to the mother)\u00a0and uterus lining, linked to\u00a0the\u00a0growth of the baby\u00a0<\/li>\n<\/ul>\n\n\n\n
The\u00a0result of these\u00a0markers\u00a0may\u00a0help evaluate the placental and baby\u2019s health (abnormal levels of markers may\u00a0indicate\u00a0poor or abnormal formation of the placenta)5<\/a><\/sup>.\u00a0This result is then\u00a0combined with ultrasound scanning tests\u00a0(especially\u00a0nuchal translucency\u00a0(NT)) and\u00a0the\u00a0mother\u2019s\u00a0age to estimate\u00a0the possible\u00a0risk 3<\/a><\/sup>.\u00a0<\/p>\n\n\n\n
This\u00a0test\u00a0is usually performed between the 10^{th<\/sup>\u00a0and 13^{th<\/sup>\u00a0weeks\u00a0+6 days\u00a0of gestation (pregnancy)}}6<\/a><\/sup>.\u00a0Abnormal levels (too high or too low) may help\u00a0indicate\u00a0increased risk\u00a0of conditions like:\u00a0<\/p>\n\n\n\n
\n
Down\u00a0Syndrome:<\/strong>\u00a0(Trisomy 21-A genetic defect caused by an extra copy of chromosome 21)\u00a0Associated with high \u03b2-hCG\u00a0and\u00a0low PAPP-A\u00a0<\/li>\n\n\n\n
Edwards\u00a0Syndrome:<\/strong>\u00a0(Trisomy 18-\u00a0<\/strong>A genetic defect caused by an extra copy of chromosome 18)\u00a0Associated with low \u03b2-hCG\u00a0and low PAPP-A3<\/a><\/sup>\u00a0<\/li>\n<\/ul>\n\n\n\n
However, for confirmation, the doctors might prescribe several other diagnostic tests.\u00a0<\/p>\n\n\n\n
<\/span>What Is a Triple Marker Test?<\/strong><\/span><\/h2>\n\n\n\nA triple market test is also a\u00a0pregnancy\u00a0screening test, but it is usually performed during the second trimester\u00a0(4^{th<\/sup>\u2013 6^{th<\/sup>\u00a0month)\u00a0of pregnancy. This test helps assess the risk of several genetic disorders in the baby,\u00a0by evaluating\u00a0certain markers in the mother\u2019s blood, along with\u00a0the\u00a0mother\u2019s age,\u00a0during the pregnancy periods. This, in turn,\u00a0helps\u00a0evaluate\u00a0whether further detailed\u00a0diagnostic\u00a0testing\u00a0for specific conditions\u00a0may be needed or not}}2<\/a>,7<\/a><\/sup>.\u00a0<\/p>
<\/div>

Feature<\/strong>\u00a0<\/td>	Double Marker Test<\/strong>\u00a0<\/td>	Triple Marker Test<\/strong>\u00a0<\/td><\/tr>
Type\u00a0of test\u00a0<\/td>	Laboratory, simple blood collection^{3<\/a><\/sup>\u00a0<\/td>}	Laboratory, simple blood collection^{7<\/a><\/sup>\u00a0<\/td><\/tr>}
Trimester & timing\u00a0<\/td>	First trimester,\u00a0between the 10 and 13 weeks, 6 days of gestation^{6<\/a><\/sup>\u00a0<\/td>}	Second trimester,\u00a0between 15 and 22 weeks\u202fof gestation^{6<\/a><\/sup>\u00a0<\/td><\/tr>}
Markers measured\u00a0<\/td>	\u03b2-hCG\u00a0& PAPP-A^{4<\/a><\/sup>\u00a0<\/td>}	AFP,\u00a0hCG, uE3^{7<\/a><\/sup><\/td><\/tr>}
Conditions screened\u00a0<\/td>	Down syndrome, Edward syndrome^{3<\/a><\/sup>\u00a0<\/td>}	Down syndrome (T21), Edward syndrome (T18)^{7<\/a><\/sup>,\u202fneural tube defects8<\/a><\/sup>\u00a0<\/td><\/tr>}
Interpretation\u00a0<\/td>	Results may be assessed\u00a0as\u00a0high or low risk\u00a0by combining the biomarker values with\u00a0the\u00a0mother\u2019s\u00a0age and NT scan;\u00a0estimated high-risk cases might be followed with other diagnostic tests^{3<\/a><\/sup>\u00a0<\/td>}	Results of the test may indicate the high or low risk of developing certain chromosomal conditions and neural tube effects; estimated high risk cases might be followed with other diagnostic tests^{2<\/a><\/sup>\u00a0<\/td><\/tr>}
Detection rate\u00a0<\/td>	Detection rate is\u00a0higher\u00a0when combined\u00a0with\u00a0an\u00a0NT scan and\u00a0mother\u2019s\u00a0age\u00a0(around\u00a0~82-95%\u00a0for\u00a0certain genetic disorders, with some 5-7% false positives)^{10<\/a><\/sup>\u00a0<\/td>}	Detection\u00a0depends on markers and mother\u2019s age (around\u00a067% to 77% of cases are detected right)^{10<\/a><\/sup>\u00a0<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<\/span>\u202fHow Do These Tests Work Together?<\/strong><\/span><\/h2>\n\n\n\nThe\u00a0double marker and triple marker tests\u00a0are not competing tests; they are often performed during different stages of pregnancy to assess\u00a0the\u00a0baby\u2019s health. The double marker test is performed during the first trimester,\u00a0while\u00a0the\u00a0triple marker is performed during the second trimester3<\/a>,6<\/a>,7<\/a><\/sup>.\u00a0<\/p>\n\n\n\n The double marker test primarily\u00a0assesses\u00a0the risks of genetic conditions. Since it is done early, it helps doctors decide sooner if any additional or more detailed tests are needed. The triple marker acts as a follow-up screening test, especially when\u00a0the\u00a0first-trimester screening test was missed, if the results during\u00a0the\u00a0double marker test showed high risk or any additional assessment is required, or if the doctor wants a broader evaluation, including neural tube defects.\u00a0<\/p>\n\n\n\n If the double marker test performed shows low risks, no further marker testing may\u00a0be advised\u00a0by the doctor. If the double marker was missed, the triple marker test becomes an important alternative. In some cases,\u00a0the triple marker test may be used as an additional screening tool depending on clinical need.\u00a0However, combining screening tests from the first and second trimesters is said to improve the chances of detecting problems compared to doing just one test6<\/a><\/sup>.<\/p>\n\n\n\n <\/span>When to Take These Tests?<\/strong><\/span><\/h2>\n\n\n\nThere is a\u00a0difference between double marker and triple marker tests\u00a0in their timeline.\u00a0<\/p>\n\n\n\n\nDouble Marker Test:<\/strong>\u00a0Usually performed during the first trimester of pregnancy,\u00a0between\u00a010 and 13 weeks, 6 days of gestation, ideally along with NT scan6<\/a><\/sup>.\u00a0During this period the levels of \u03b2-hCG\u00a0and PAPP-A may be more accurate\u00a0in detecting\u00a0risk of chromosomal conditions. The baby is at an early stage, so\u00a0the doctors still have time to do confirmatory tests early3<\/a><\/sup>.\u00a0<\/li>\n\n\n\n Triple Marker Test:<\/strong>\u00a0Usually performed during the second trimester of pregnancy, between 15 and 22 weeks of gestation4<\/a>,6<\/a><\/sup>. This test is important because it may help assess the risk if the marker test was missed or they had shown high risk during the first trimester test6<\/a><\/sup>.\u00a0<\/li>\n<\/ul>\n\n\n\n<\/span>How Are These Tests Done?<\/strong><\/span><\/h2>\n\n\n\nBoth the\u00a0double marker and triple marker tests\u00a0are very\u00a0simple\u00a0tests\u00a0which are performed during pregnancy. These are:\u00a0<\/p>\n\n\n\n\nSimple\u00a0Blood\u00a0Tests:<\/strong>\u00a0A small amount of blood may be collected from the mother using a needle6<\/a><\/sup>.\u00a0The sample is then analysed in a laboratory to measure specific markers.\u00a0<\/li>\n\n\n\n Needs\u00a0No\u00a0Major Preparation:\u00a0<\/strong>Usually may not need any fasting or any special preparation.\u00a0Blood tests during pregnancy\u00a0testing generally may not require any kind of preparation before sample collection11<\/a><\/sup>.<\/li>\n\n\n\n Non-Invasive and\u00a0Safe:<\/strong>\u00a0Since the process involves only blood sample collection, it may be referred\u00a0to\u00a0as non-invasive3<\/a><\/sup>, as it causes no harm to the baby and mother11<\/a><\/sup>.\u00a0They\u00a0are generally\u00a0safe and commonly performed as part of pregnancy\u00a0care.\u00a0<\/li>\n<\/ul>\n\n\n\n<\/span>Who Should Take These Tests?<\/strong><\/span><\/h2>\n\n\n\nThe double marker and triple marker tests are recommended to be performed by women coming under the following category:\u00a0<\/p>\n\n\n\n1. All Pregnant Women<\/strong>\u00a0<\/h3>\n\n\n\nThese tests are\u00a0generally offered to all pregnant women as part of routine pregnancy care.\u00a0(Triple marker\u00a0may be\u00a0considered less routine if double marker test is performed in the first trimester).\u00a0They\u00a0are\u00a0mainly performed during the early stages of pregnancy.\u00a0<\/p>\n\n\n\n2. High-Risk Groups<\/strong><\/h3>\n\n\n\nThese tests are especially important for women with higher chances of chromosomal abnormalities.\u00a0<\/p>\n\n\n\n\nAged 35 or older during pregnancy3<\/a><\/sup>\u00a0<\/li>\n\n\n\n Previous pregnancy with abnormalities\u00a0<\/li>\n\n\n\n Family history\u00a0of genetic birth defects6<\/a><\/sup>\u00a0<\/li>\n\n\n\n Abnormal scanning result\u00a0<\/li>\n<\/ul>\n\n\n\n<\/span>Advantages of Double Marker and Triple Marker Tests<\/strong><\/span><\/h2>\n\n\n\nThe following are some advantages of double marker and triple marker tests:\u00a0<\/p>\n\n\n\n\nEarly Risk Detection:\u00a0<\/strong>Help identify the risks of genetic disorders in the first trimester, allowing\u00a0timely\u00a0monitoring and planning. Provides\u00a0additional assessment in the second trimester6<\/a><\/sup>.<\/li>\n\n\n\n Non-Invasive:\u00a0<\/strong>Both\u00a0tests involve only a simple blood sample from the mother, making them safe for both the mother and the baby3<\/a>,11<\/a><\/sup>.\u00a0There is no direct contact with\u00a0the\u00a0baby, which makes these tests risk-free.\u00a0<\/li>\n\n\n\n Helps in Decision Making:<\/strong>\u00a0The results of these tests help\u00a0doctors decide whether more definitive diagnostic tests, such as amniocentesis or chorionic villus sampling4<\/a>,6<\/a><\/sup>,\u00a0are needed. This might make sure that only those pregnancies with high risks are\u00a0subjected to\u00a0further testing.\u00a0<\/li>\n\n\n\n Better Overall Pregnancy Monitoring:<\/strong>\u00a0When used together at different stages, these tests provide a more complete view of the baby\u2019s health, helping track any potential concerns over time rather than relying on a single test6<\/a><\/sup>.<\/li>\n\n\n\n Widely Available and Convenient:<\/strong>\u00a0These tests are commonly performed in most labs and hospitals,\u00a0making them easily accessible and convenient to include as part of routine pregnancy care.\u00a0<\/li>\n<\/ul>\n\n\n\n<\/span>Limitations of Double and Triple Marker Tests<\/strong><\/span><\/h2>\n\n\n\nThe following says some limitations of maker tests:\u00a0<\/p>\n\n\n\n\nNon-Diagnostic:<\/strong>\u00a0These are just screening tests, which means they only estimate the chance or risk of certain conditions. They cannot confirm whether the baby actually has a genetic condition or birth defect. Even if a high risk is estimated, further diagnosis is required for confirmation2<\/a><\/sup>.<\/li>\n\n\n\n False Positives\/Negatives Possible:<\/strong>\u00a0The results are based on probability, so they are not 100% accurate. Sometimes, the test may show a high risk even when the baby is healthy (false positive)2<\/a><\/sup>,\u00a0which can cause unnecessary worry. In other cases, it may show low risk even if a condition is present (false negative), meaning some cases can be missed.\u00a0<\/li>\n\n\n\n May Need Further Testing:<\/strong>\u00a0If the results indicate an increased risk, doctors usually recommend more accurate diagnostic tests, such as amniocentesis or chorionic\u00a0villus\u00a0sampling\u00a0to confirm the diagnosis2<\/a>,6<\/a><\/sup>.<\/li>\n\n\n\n Results can be Influenced by Other Factors:\u00a0<\/strong>Factors like the mother\u2019s age, weight, medical history, or incorrect pregnancy dating can sometimes affect the results, which is why these tests are always interpreted along with other clinical findings3<\/a>,6<\/a><\/sup>.<\/li>\n<\/ul>\n\n\n\n<\/span>Safety and Risks of Double Marker and Triple Marker Tests<\/strong><\/span><\/h2>\n\n\n\nThese marker tests are considered to be safe as they are non-invasive, since no complex cuts or breaks are made for screening. Hence, they have very limited risks.\u00a0Risks\u00a0may be there\u00a0during sample collection only, which will not affect the baby. Even for the mother,\u00a0these\u00a0tests cause very minor side effects during blood collection like\u00a0discomfort, pain or\u00a0bruise at the injection site after blood collection,\u00a0which usually subside soon after6<\/a>,11<\/a><\/sup>.<\/p>\n\n\n\n <\/span>Conclusion<\/strong><\/span><\/h2>\n\n\n\nThe double and triple marker tests are simple\u00a0blood\u00a0tests\u00a0done\u00a0during pregnancy to assess\u00a0the\u00a0risk\u00a0of certain genetic conditions in the developing baby. Doing them at the right time is important for better accuracy.\u00a0However, it is important to remember that these are\u00a0just screening tests and\u00a0not confirmatory tests,\u00a0and abnormal results do not always mean\u00a0that there\u2019s an issue with\u00a0the\u00a0baby.\u00a0Always consult your doctor<\/a><\/strong> to properly understand the results and decide the next steps if needed.\u00a0<\/p>\n\n\n\n <\/span>Frequently Asked Questions (FAQs)<\/strong><\/span><\/h2>\n\n\n\nWhich is better, double marker or triple marker?<\/strong>\u00a0<\/strong> The double marker\u00a0and triple marker tests are both useful\u00a0as they\u00a0are\u00a0done in different stages of pregnancy.\u00a0Double marker\u00a0is done earlier in pregnancy, allowing early detection of risks such as Down syndrome and giving more time for further testing and decisions. The triple marker test is done later and is mainly used if the first test is missed or for additional assessment6<\/a><\/sup>.\u00a0Therefore, both tests are useful;\u00a0we cannot say that one is strictly better than the other.\u00a0<\/p> <\/div> Can I take both the Double Marker and Triple Marker tests in the same pregnancy?<\/strong>\u00a0<\/strong> Both double marker and triple marker tests are used to assess the risks. So even if the first tests show low risk, sometimes the doctors might suggest\u00a0a\u00a0triple mark6<\/a><\/sup>.\u00a0Therefore,\u00a0it\u00a0is ok to take both tests in the same pregnancy.\u00a0<\/p> <\/div> Can these tests detect neural tube defects?<\/strong>\u00a0<\/strong> The triple marker test may be able to\u00a0assess the risk of\u00a0neural defects as it includes\u00a0AFP testing, which is crucial for\u00a0the\u00a0brain or spinal cord development of the baby8<\/a><\/sup>.\u00a0<\/p> <\/div> What is the difference between these tests and more advanced tests like NIPT?<\/strong>\u00a0<\/strong> The major difference\u00a0between these marker tests and\u00a0non-invasive prenatal testing\u00a0<\/strong>(NIPT)\u00a0tests is that double and triple marker tests\u00a0use natural components,\u00a0proteins or hormones6<\/a><\/sup>,\u00a0while NIPT tests\u00a0use small fragments of\u202fbaby\u2019s DNA\u00a0which might be floating in the mother\u2019s blood12<\/a><\/sup>.\u00a0Both are used to assess the risk of genetic abnormalities.\u00a0According\u00a0to\u00a0current standards NIPT\u00a0has more than 99%\u00a0detection rate\u00a0for\u00a0Down syndrome13<\/a><\/sup>.<\/p> <\/div> Can these tests determine the baby\u2019s gender?<\/strong>\u00a0<\/strong> No, the\u00a0double marker\u00a0<\/strong>and\u00a0<\/strong>triple marker tests\u00a0<\/strong>cannot determine the baby\u2019s\u00a0<\/strong>gender.<\/strong>\u00a0These are\u00a0screening tests\u00a0that measure certain hormones and proteins in the mother\u2019s blood to assess the risk of chromosomal conditions like\u00a0Down syndrome. They do\u00a0not analyse sex chromosomes in a way that reveals gender.<\/strong>\u00a0<\/p> <\/div> <\/div>\n\n\n\n<\/span>References<\/strong><\/span><\/h2>\n\n\n\n1. NHS. Screening tests in pregnancy [Internet]. National Health Service; [cited 2026 Apr 14]. Available from: https:\/\/www.nhs.uk\/pregnancy\/your-pregnancy-care\/screening-tests\/\u00a0<\/a><\/p>\n\n\n\n 2. Maternal Serum Marker Screening. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK132135\/\u00a0<\/a><\/p>\n\n\n\n 3. Shiefa S, Amargandhi M, Bhupendra J, Moulali S, Kristine T. First Trimester Maternal Serum Screening Using Biochemical Markers PAPP-A and Free \u03b2-hCG for Down Syndrome, Patau Syndrome and Edward Syndrome.\u00a0Ind J Clin Biochem<\/em>. 2013;28(1):3-12. doi:10.1007\/s12291-012-0269-9. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/24381414\/<\/a><\/p>\n\n\n\n 4. Triple-marker test as screening for Down syndrome: a meta-analysis. 1998. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK67524\/<\/a>\u00a0<\/p>\n\n\n\n 5. Ghasemi-Tehrani H, Sadeghian A, Entezari R. Relationship Between Pregnancy Complications and Serum Pregnancy Associated-Plasma-Protein-A and Free-\u03b2-Human Chorionic Gonadotropin in the First Trimester Among Iranian Women.\u00a0J Family Reprod Health<\/em>. 2017;11(4):219-224.\u00a0Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC6168753\/<\/a><\/p>\n\n\n\n 6. Maines J, Langaker MD. Prenatal Genetic Screening. 2025. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK557702\/<\/a>\u00a0<\/p>\n\n\n\n 7. Vranken G, Reynolds T, Van Nueten J. Medians for second-trimester maternal serum markers: geographical differences and variation caused by median multiples-of-median equations.\u00a0J Clin Pathol<\/em>. 2006;59(6):639-644. doi:10.1136\/jcp.2005.034272. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/16731605\/<\/a><\/p>\n\n\n\n 8. Alpha-Fetoprotein (AFP) Test. 2024. Available from: https:\/\/medlineplus.gov\/lab-tests\/alpha-fetoprotein-afp-test\/\u00a0<\/a><\/p>\n\n\n\n 9. Estriol (Maternal Serum). Available from: https:\/\/www.gov.nl.ca\/labformulary\/formulary\/estriol-maternal-serum\/\u00a0<\/a><\/p>\n\n\n\n 10. Park SY, Jang IA, Lee MA, Kim YJ, Chun SH, Park MH. Screening for chromosomal abnormalities using combined test in the first trimester of pregnancy.\u00a0Obstet Gynecol Sci<\/em>. 2016;59(5):357. doi:10.5468\/ogs.2016.59.5.357. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/27668198\/<\/a><\/p>\n\n\n\n 11. Prenatal Panel. 2024. Available from: https:\/\/medlineplus.gov\/lab-tests\/prenatal-panel\/\u00a0<\/a><\/p>\n\n\n\n 12. What is noninvasive prenatal testing (NIPT) and what disorders can it screen for? 2021. Available from: https:\/\/medlineplus.gov\/genetics\/understanding\/testing\/nipt\/\u00a0<\/a><\/p>\n\n\n\n 13. Carbone L, Cariati F, Sarno L, et al. Non-Invasive Prenatal Testing: Current Perspectives and Future Challenges.\u00a0Genes<\/em>. 2020;12(1):15. doi:10.3390\/genes12010015. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/33374411\/<\/a><\/p>\n\n\n\n Disclaimer<\/em><\/strong>: The information provided here is for educational\/awareness purposes only and is not intended to be a substitute for medical treatment by a healthcare professional and should not be relied upon to diagnose or treat any medical condition. The reader should consult a registered medical practitioner to determine the appropriateness of the information and before consuming any medication. PharmEasy does not provide any guarantee or warranty (express or\u00a0implied) regarding the accuracy, adequacy, completeness, legality, reliability or usefulness of the information; and disclaims any liability arising thereof.<\/em>\u00a0<\/p>\n\n\n\n Links and product recommendations in the information<\/em>\u00a0provided here are advertisements of third-party products available on the website. PharmEasy does not make any representation on the accuracy or suitability of such products\/services. Advertisements do not influence the editorial decisions or content. The information in this blog is subject to change without notice. The authors and administrators reserve the right to modify, add, or remove content without notification. It is your responsibility to review this disclaimer regularly for any changes.<\/em><\/p>\n<\/body><\/html>\n \r\n \r\n \r\n \r\n <\/a>\r\n <\/span>\r\n<\/div>\r\n \r\n \r\n <\/a>\r\n <\/span>\r\n<\/div><\/div>","protected":false},"excerpt":{"rendered":"Introduction The\u00a0pregnancy period involves several checkups, which\u00a0are\u00a0essential to\u00a0ensure that the\u00a0baby is growing well and staying healthy.\u00a0An\u00a0important part of these check-ups is\u00a0early pregnancy (prenatal)\u00a0screening, which helps doctors understand if there\u00a0are\u00a0any chances\u00a0of certain health conditions in the baby early on. These are simple screening tests, which are different from diagnostic procedures1.\u00a0 A type\u00a0of screening tests\u00a0employed for this [\u2026]","protected":false},"author":164,"featured_media":275120,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_wp_rev_ctl_limit":""},"categories":[10435],"tags":[14181],"acf":[],"_embedded":{"wp:featuredmedia":[{"source_url":"https:\/\/pharmeasy.in\/blog\/wp-content\/uploads\/2026\/04\/double-marker-and-triple-marker-test.webp"}]},"_links":{"self":[{"href":"https:\/\/pharmeasy.in\/blog\/wp-json\/wp\/v2\/posts\/274871"}],"collection":[{"href":"https:\/\/pharmeasy.in\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharmeasy.in\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharmeasy.in\/blog\/wp-json\/wp\/v2\/users\/164"}],"replies":[{"embeddable":true,"href":"https:\/\/pharmeasy.in\/blog\/wp-json\/wp\/v2\/comments?post=274871"}],"version-history":[{"count":8,"href":"https:\/\/pharmeasy.in\/blog\/wp-json\/wp\/v2\/posts\/274871\/revisions"}],"predecessor-version":[{"id":275154,"href":"https:\/\/pharmeasy.in\/blog\/wp-json\/wp\/v2\/posts\/274871\/revisions\/275154"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pharmeasy.in\/blog\/wp-json\/wp\/v2\/media\/275120"}],"wp:attachment":[{"href":"https:\/\/pharmeasy.in\/blog\/wp-json\/wp\/v2\/media?parent=274871"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharmeasy.in\/blog\/wp-json\/wp\/v2\/categories?post=274871"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharmeasy.in\/blog\/wp-json\/wp\/v2\/tags?post=274871"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}}